Soleno Therapeutics (SLNO) Given a $4.00 Price Target by Noble Financial Analysts

Soleno Therapeutics (NASDAQ:SLNO) has been given a $4.00 price target by investment analysts at Noble Financial in a research note issued on Wednesday. The firm presently has a “buy” rating on the stock. Noble Financial’s target price suggests a potential upside of 116.22% from the stock’s current price.

SLNO has been the topic of a number of other research reports. Maxim Group set a $4.00 price target on shares of Soleno Therapeutics and gave the stock a “buy” rating in a report on Monday, April 2nd. ValuEngine upgraded shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of Soleno Therapeutics opened at $1.85 on Wednesday, MarketBeat reports. Soleno Therapeutics has a 52 week low of $1.76 and a 52 week high of $1.77.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, May 16th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08).

In other Soleno Therapeutics news, major shareholder Larry N. Feinberg bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was bought at an average cost of $1.80 per share, with a total value of $90,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 69.75% of the company’s stock.

Large investors have recently bought and sold shares of the company. Birchview Capital LP bought a new stake in shares of Soleno Therapeutics during the fourth quarter worth about $1,032,000. 683 Capital Management LLC increased its position in shares of Soleno Therapeutics by 462.7% during the fourth quarter. 683 Capital Management LLC now owns 844,112 shares of the company’s stock worth $1,519,000 after acquiring an additional 694,112 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Soleno Therapeutics during the fourth quarter worth about $1,647,000. 45.31% of the stock is owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply